SEC Form 4 · accession 0001104659-26-084300
ADIAL PHARMACEUTICALS, INC. · ADIL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Coastlands Capital LP
10% Owner
Period of report
Jul 14, 2026
Accepted (ET)
Jul 16, 2026 · 5:08 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001513525
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 14, 2026 | P | 2,000 | $2.65 | A | 387,075 | I | By Coastlands Capital LP |
| Common StockF1 | Jul 16, 2026 | P | 1,233 | $2.75 | A | 388,308 | I | By Coastlands Capital LP |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, a Delaware limited partnership (the "Partnership"). Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein.